Stockscreener 앱 받기
399.33
0.41%
1.7765
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance - MSN
Liontrust Investment Partners LLP Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Holocene Advisors LP Invests $194.62 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
China Universal Asset Management Co. Ltd. Trims Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase - simplywall.st
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern - Seeking Alpha
Seagate, Alnylam among six companies set to join Nasdaq 100 - MSN
Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index - GuruFocus
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Gilder Gagnon Howe & Co. LLC Sells 8,487 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Eventide Asset Management LLC Sells 40,548 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Bellevue Group AG - MarketBeat
Seagate, Alnylam Are Among Six Companies Set to Join Nasdaq 100 - Bloomberg.com
Annual Changes to the Nasdaq-100 Index® - GlobeNewswire Inc.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options - Yahoo Finance
How Good Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), When It Comes To ROE? - Yahoo Finance
Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge? - simplywall.st
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 - BioSpace
Is Alnylam Pharmaceuticals Stock Built to Withstand More Downside? - Trefis
$73 Billion Non-Opioid Therapeutics Industry Assessment, - GlobeNewswire
$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $508.00 - MarketBeat
WINTON GROUP Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Announces $34.4M Convertible Notes Repurchase - GuruFocus
Alnylam Pharmaceuticals stock price target raised by Stifel to $508 - Investing.com
ALNY: Stifel Raises Price Target to $508, Maintains Buy Rating | ALNY Stock News - GuruFocus
Alnylam to repurchase $34.4 million of convertible notes - Investing.com
Alnylam Pharma Announces Convertible Notes Buyback - TipRanks
Alnylam Announces Partial Repurchase Of 1.00% Convertible Senior Notes Due 2027 - TradingView — Track All Markets
Alnylam Pharmaceuticals, Inc. Announces Partial Repurchase of Convertible Notes - TradingView — Track All Markets
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
authID (NASDAQ: AUID) PrivacyKey named 2025 PayTech Awards Best Digital Trust Solution - Stock Titan
Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario - MarketBeat
California Public Employees Retirement System Purchases 10,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.5%Here's Why - MarketBeat
Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 24%? - Yahoo Finance
How (ALNY) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals a Millionaire Maker? - Finviz
Is Alnylam Pharmaceuticals a millionaire maker? - MSN
Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative - simplywall.st
Can Alnylam Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Marshall Wace LLP Sells 30,359 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Volume & AI Optimized Trade Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesMarket Sentiment Review & Risk Controlled Daily Trade Plans - Newser
Dodge & Cox Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosInsider Buying & Short-Term Trading Alerts - Newser
Arrowstreet Capital Limited Partnership Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiples2025 Market Sentiment & Community Driven Trade Alerts - Newser
Do Alnylam Pharmaceuticals’ (ALNY) Board Moves Quietly Reframe Its Management Incentives and Risk Profile? - Yahoo Finance
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
5.96%
0.18%
자본화:
|
볼륨(24시간):